Semaglutide

Long-acting GLP-1 receptor agonist

CARD 37

CLASS	CLINICAL CATEGORY	EVIDENCE LEVEL	OVERALL STATUS
GLP-1 agonist	Type 2 diabetes / obesity	High	Approved (FDA, EMA, ANVISA)



KEY APPLICATIONS

- **Type 2 diabetes** — Approved indication
- **Obesity** — Approved indication
- **Cardiovascular risk** — Demonstrated reduction
- **Oral formulation** — Available

Designed for: type 2 diabetes and chronic weight management. Phase III trials support the labeled uses only; prescription and follow-up required.

HOW IT WORKS IN THE BODY

Semaglutide → GLP-1 receptor → Satiety and gastric emptying → Weight and blood glucose

- GLP-1 agonist with a **long half-life** .
- Demonstrated reduction **in cardiovascular** events.
- Available in subcutaneous **and oral** formulations.
- Clinically significant **weight** loss.

QUICK PRACTICAL INFO

HALF-LIFE	ROUTES STUDIED
~7 days	Subcutaneous and oral forms
PHARMACOKINETICS	**STABILITY**
Albumin binding; reduced DPP-4 degradation	Refrigerated pen before use
INTERACTIONS	**MONITORING**
Delays absorption of oral drugs	HbA1c, weight and GI tolerance

EVIDENCE & SAFETY

EVIDENCE

HIGH
ESTABLISHED CLINICAL USE

- **Phase III** trials completed.
- Indications **approved** by agencies.
- Safety profile **well characterized**.

CLINICAL CAUTION

- **Nausea** and GI changes are common.
- Contraindicated in **MTC / MEN2**.
- Monitor **retinopathy in** patients with diabetes.
- Risk of **pancreatitis** and cholelithiasis.

REGULATORY STATUS

FDA	EMA	ANVISA	WADA	Research	Off-label
Approved	Approved	Approved	Check the current list	Yes, phase III trials	Physician judgment only

CLINICAL READ IN 10 SECONDS

- Long-acting **GLP-1** agonist.
- Reduces **cardiovascular** events.
- Significant weight loss.
- **Widely approved**.

KEY REFERENCES

Manufacturer's prescribing information — FDA / EMA / ANVISA

Marso et al., 2016 — N Engl J Med

Wilding et al., 2021 — N Engl J Med 384:989–1002

Technical, informational content. It does not replace individualized clinical judgment or constitute a recommendation. No dose, protocol or source is provided.